S&P 500   0.66 (+14.63%)
DOW   0.66 (+14.63%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   0.66 (+14.63%)
DOW   0.66 (+14.63%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   0.66 (+14.63%)
DOW   0.66 (+14.63%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   0.66 (+14.63%)
DOW   0.66 (+14.63%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
Log in

NASDAQ:TTNPTitan Pharmaceuticals Stock Price, Forecast & News

$0.30
-0.01 (-3.87 %)
(As of 08/11/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.29
Now: $0.30
$0.31
50-Day Range
$0.28
MA: $0.31
$0.41
52-Week Range
$0.14
Now: $0.30
$0.76
Volume4.30 million shs
Average Volume13.59 million shs
Market Capitalization$28.30 million
P/E RatioN/A
Dividend YieldN/A
Beta0.89
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment. It also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. The company has a collaboration with Nevada Center for Behavioral Health to evaluate a medication-assisted treatment program utilizing Probuphine (buprenorphine) implant for Opioid Use Disorder (OUD) patients. Titan Pharmaceuticals, Inc. was founded in 1992 and is based in South San Francisco, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.22 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TTNP
CUSIPN/A
Phone650-244-4990

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.61 million
Book Value$0.02 per share

Profitability

Net Income$-16,460,000.00
Net Margins-437.91%

Miscellaneous

Employees23
Market Cap$28.30 million
Next Earnings Date8/14/2020 (Confirmed)
OptionableOptionable
$0.30
-0.01 (-3.87 %)
(As of 08/11/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TTNP News and Ratings via Email

Sign-up to receive the latest news and ratings for TTNP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Titan Pharmaceuticals (NASDAQ:TTNP) Frequently Asked Questions

How has Titan Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Titan Pharmaceuticals' stock was trading at $0.2445 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TTNP shares have increased by 21.0% and is now trading at $0.2958.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Titan Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Titan Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Titan Pharmaceuticals
.

When is Titan Pharmaceuticals' next earnings date?

Titan Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020.
View our earnings forecast for Titan Pharmaceuticals
.

How can I listen to Titan Pharmaceuticals' earnings call?

Titan Pharmaceuticals will be holding an earnings conference call on Friday, August 14th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Titan Pharmaceuticals' earnings last quarter?

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) issued its earnings results on Friday, May, 15th. The specialty pharmaceutical company reported ($0.06) EPS for the quarter. The specialty pharmaceutical company had revenue of $1.34 million for the quarter. Titan Pharmaceuticals had a negative net margin of 437.91% and a negative return on equity of 1,909.37%.
View Titan Pharmaceuticals' earnings history
.

When did Titan Pharmaceuticals' stock split? How did Titan Pharmaceuticals' stock split work?

Titan Pharmaceuticals shares reverse split on the morning of Friday, January 25th 2019. The 1-6 reverse split was announced on Thursday, January 24th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 24th 2019. An investor that had 100 shares of Titan Pharmaceuticals stock prior to the reverse split would have 17 shares after the split.

What price target have analysts set for TTNP?

1 Wall Street analysts have issued 1 year price objectives for Titan Pharmaceuticals' stock. Their forecasts range from $1.00 to $1.00. On average, they anticipate Titan Pharmaceuticals' share price to reach $1.00 in the next twelve months. This suggests a possible upside of 238.1% from the stock's current price.
View analysts' price targets for Titan Pharmaceuticals
.

Has Titan Pharmaceuticals been receiving favorable news coverage?

News stories about TTNP stock have been trending negative on Tuesday, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Titan Pharmaceuticals earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave news stories about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future.
View the latest news about Titan Pharmaceuticals
.

Are investors shorting Titan Pharmaceuticals?

Titan Pharmaceuticals saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 5,700,000 shares, an increase of 41.8% from the January 31st total of 4,020,000 shares. Based on an average trading volume of 12,030,000 shares, the days-to-cover ratio is presently 0.5 days.
View Titan Pharmaceuticals' Short Interest
.

Who are some of Titan Pharmaceuticals' key competitors?

What other stocks do shareholders of Titan Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Titan Pharmaceuticals investors own include Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), BioNano Genomics (BNGO), Gran Tierra Energy (GTE), Matinas BioPharma (MTNB), OrganiGram (OGI), Zosano Pharma (ZSAN), Novan (NOVN), AEterna Zentaris (AEZS) and Cannabics Pharmaceuticals (CNBX).

Who are Titan Pharmaceuticals' key executives?

Titan Pharmaceuticals' management team includes the following people:
  • Dr. Marc Rubin, Exec. Chairman (Age 64)
  • Mr. Sunil Bhonsle, Pres, CEO, Principal Financial Officer & Director (Age 69)
  • Dr. Katherine L. Beebe-DeVarney Ph.D., Exec. VP & Chief Scientific Officer (Age 58)
  • Mr. Dane D. Hallberg, Exec. VP & Chief Commercial Officer (Age 50)

What is Titan Pharmaceuticals' stock symbol?

Titan Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTNP."

Who are Titan Pharmaceuticals' major shareholders?

Titan Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.15%) and UBS Group AG (0.12%). Company insiders that own Titan Pharmaceuticals stock include James R Mcnab, Marc Rubin and Sunil Bhonsle.
View institutional ownership trends for Titan Pharmaceuticals
.

Which institutional investors are buying Titan Pharmaceuticals stock?

TTNP stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC, and UBS Group AG. Company insiders that have bought Titan Pharmaceuticals stock in the last two years include James R Mcnab, Marc Rubin, and Sunil Bhonsle.
View insider buying and selling activity for Titan Pharmaceuticals
.

How do I buy shares of Titan Pharmaceuticals?

Shares of TTNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Titan Pharmaceuticals' stock price today?

One share of TTNP stock can currently be purchased for approximately $0.30.

How big of a company is Titan Pharmaceuticals?

Titan Pharmaceuticals has a market capitalization of $28.30 million and generates $3.61 million in revenue each year. The specialty pharmaceutical company earns $-16,460,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis. Titan Pharmaceuticals employs 23 workers across the globe.

What is Titan Pharmaceuticals' official website?

The official website for Titan Pharmaceuticals is www.titanpharm.com.

How can I contact Titan Pharmaceuticals?

Titan Pharmaceuticals' mailing address is 400 OYSTER POINT BLVD SUITE 505, SAN FRANCISCO CA, 94080. The specialty pharmaceutical company can be reached via phone at 650-244-4990 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.